Mark is founder and Managing Director of Mercia Fund Management (MFM). He has a degree in Human Biology from Oxford, PhD from King's College London in molecular immunology and an MBA from Warwick Business School.
Prior to joining Mercia Technology Seed Fund, Mark was a research fellow at the Department of Pharmacology (University of Oxford). He has played leading roles within Isis Innovation and was VP Corporate Development at Oxxon Therapeutics Inc.
Mark has over 15 years experience in the commercialisation of life science opportunities in the biotech, niche pharma, medtech and diagnostic fields. So far he has raised circa 30m into his portfolio companies in addition to MFM's own investment.